Familial hypercholesterolaemia: identification and management
KEYWORDS: people, healthcare, disease, therapy, coronary, healthcare professionals, professionals, children, heart disease, coronary heart, heart, concentration, risk, ldl-c, drug

risk, people should receive clear and appropriate educational information about FH, the process of family testing, DNA testing and the measurement of LDL-C concentration. [2008] 1.4.1.2 A healthcare professional with expertise in FH should provide information to people with FH on their specific level of risk of coronary heart disease, its implications for them and their families, lifestyle advice and treatment options. [2008] 1.4.1.3 Healthcare professionals with expertise in FH should encourage people with FH to contact their relatives to inform them of their potential risk and so that cascade testing can take place. [2008] 1.4.1.4 When considering cascade testing, a healthcare professional with expertise in FH should offer to facilitate the sharing of information about FH with family members. [2008] 1.4.1.5 Healthcare professionals should offer people with FH and their families written advice and information about patient support groups. [2008] 1.4.2 Information and counselling on contraception for women and girls with FH 1.4.2.1 When lipid-modifying drug therapy is first considered for women and girls, the risks for future pregnancy and the fetus while taking lipid-modifying drug therapy should be discussed. This discussion should be revisited at least annually. [2008] 1.4.2.2 Healthcare professionals should give women and girls with FH
